Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IMRN

Immuron Limited ADR

1.11

Jul 24 • 3:53 PM ET -0.06 (-5.13%)

1.11

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology Australia Nano NASD

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

Scroll to Statements

Index	-
Market Cap	8.96M
Enterprise Value	2.29M
Income	-2.99M
Sales	4.83M
Book/sh	1.07
Cash/sh	0.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Mar 02, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	1.85
P/B	1.04
P/C	1.34
P/FCF	-
EV/EBITDA	-
EV/Sales	0.47
Quick Ratio	6.83
Current Ratio	8.04
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.48
EPS next Y	-0.01
EPS next Q	-
EPS this Y	98.57%
EPS next Y	-26.89%
EPS next 5Y	-
EPS past 3/5Y	-17.17% -5.64%
Sales past 3/5Y	104.11% 22.82%
EPS Y/Y TTM	43.46%
Sales Y/Y TTM	11.90%
EPS Q/Q	36.26%
Sales Q/Q	3.85%
Earnings	Feb 25 BMO
EPS/Sales Surpr.	- 3.06%

Insider Own	-
Insider Trans	-
Inst Own	1.05%
Inst Trans	59.14%
ROA	-33.89%
ROE	-39.51%
ROIC	-34.26%
Gross Margin	63.68%
Oper. Margin	-78.35%
Profit Margin	-61.85%
SMA20	-5.01%
SMA50	-3.81%
SMA200	-3.38%
Trades

Shs Outstand	8.17M
Shs Float	3.25M
Short Float	2.43%
Short Ratio	0.32
Short Interest	0.08M
52W High	2.39 -53.56%
52W Low	0.68 64.08%
Volatility	9.35% 10.97%
ATR (14)	0.12
RSI (14)	46.50
Beta	1.09
Rel Volume	0.08
Avg Volume	247.74K
Volume	19,201

Perf Week	-8.26%
Perf Month	2.78%
Perf Quarter	25.94%
Perf Half Y	11.33%
Perf YTD	45.57%
Perf Year	-36.21%
Perf 3Y	-44.86%
Perf 5Y	-77.11%
Perf 10Y	-
Recom	2.00
Target Price	4.00
Prev Close	1.17
Price	1.11
Change	-5.13%

Jul-20-26 06:00AM	Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar (GlobeNewswire) -6.61%
Jul-16-26 06:00AM	Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year (GlobeNewswire) -5.04%
Jul-06-26 06:00AM	Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy (GlobeNewswire)
Apr-22-26 09:00AM	Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 (ACCESSWIRE) -5.29%
Apr-17-26 06:00AM	Immuron Double Digit 3Q Sales Growth (GlobeNewswire) +13.35%
11:05AM	Loading…
Mar-05-26 11:05AM	Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target (ACCESSWIRE)
06:00AM	Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference (GlobeNewswire)
Feb-25-26 06:00AM	Immuron Reports HY26 Results and Strategic Reset (GlobeNewswire) +17.14%
Jan-22-26 06:00AM	Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target (ACCESSWIRE)
Jan-19-26 06:00AM	Immuron Reports Continued Sales Growth (GlobeNewswire)
Dec-15-25 12:36PM	Immuron (IMRN) Struggles After Announcing Trial Results (Insider Monkey)
Dec-03-25 06:00AM	Immuron New U.S. Department of Defense Award & Clinical Trial Update (GlobeNewswire) -10.92%
Nov-05-25 06:00AM	Immuron IMM-529 IND approved by FDA (GlobeNewswire) -12.72%
Oct-31-25 06:00AM	Immuron Announces Clinical Trial Update (GlobeNewswire) -5.94%
Oct-17-25 11:07AM	Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target (Newsfile)
06:00AM	Loading…
Oct-13-25 06:00AM	Immuron Q1 FY26 YoY growth (GlobeNewswire)
Oct-08-25 06:00AM	Immuron Submits IMM-529 IND to FDA (GlobeNewswire)
Oct-02-25 06:00AM	Immuron Letter to Shareholders - Projects Update (GlobeNewswire) +7.86%
Sep-30-25 03:01PM	Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales (Insider Monkey)
Aug-26-25 10:29PM	Immuron partners with InvestorHub (GlobeNewswire)
Jul-17-25 06:00AM	Immuron - FY25 global sales exceed projection, up 49% on prior year (GlobeNewswire)
May-30-25 06:00AM	Immuron Letter to Shareholders: Projects Update (GlobeNewswire)
Apr-10-25 06:00PM	Immuron Travelan highest sales in history (GlobeNewswire)
Mar-05-25 06:00AM	Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) (GlobeNewswire) +8.20%
Feb-18-25 07:00AM	Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now (GlobeNewswire)
Jan-17-25 06:00AM	Immuron Travelan continued strong sales growth (GlobeNewswire) +8.59%
Jan-15-25 06:00AM	Immuron Announces New Research Collaboration targeting Antimicrobial Resistance (GlobeNewswire)
Jan-14-25 06:00AM	Immuron Announces Travelan Clinical Trial Update (GlobeNewswire)
Dec-06-24 09:17AM	UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
08:35AM	Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th (GlobeNewswire)
03:45PM	Loading…
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
08:35AM	Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th (GlobeNewswire)
Dec-02-24 06:00AM	Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th (GlobeNewswire)
Nov-21-24 06:33PM	Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event (GlobeNewswire)
Nov-18-24 08:30AM	Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-16-24 06:00AM	Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference (GlobeNewswire) +7.49%
Oct-15-24 06:00AM	Immuron Travelan continued strong sales growth (GlobeNewswire) -15.76%
Oct-04-24 06:30AM	NMRC Reports Results for Campylobacter Controlled Human Infection Model Study (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire) +11.92%
Sep-05-24 11:54AM	Immuron Plans Phase 2 Trial for IMM-529 following FDA review (GlobeNewswire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire) +8.06%
Aug-16-24 06:00AM	Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan (GlobeNewswire)
Aug-15-24 06:14PM	Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference (GlobeNewswire)
Aug-07-24 06:00AM	Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect (GlobeNewswire)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-15-24 08:00AM	Immuron announces record Travelan sales globally, Australia and USA (GlobeNewswire) +6.36%
Jul-02-24 06:00AM	Immuron requests pre-IND meeting for IMM-529 with FDA filing (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 06:00AM	Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference (GlobeNewswire)
May-31-24 06:00AM	Immuron CEO Steven Lydeamore to present at Peak Sky High (GlobeNewswire)
06:00AM	Immuron Board Changes (GlobeNewswire)
May-08-24 07:50AM	Presenting on the Emerging Growth Conference 70 Day 2 on May 9 Register Now (GlobeNewswire)
May-07-24 07:00AM	Presenting on the Emerging Growth Conference 70 Day 1 on May 8 Register Now (GlobeNewswire)
06:00AM	Immuron Limited to Present at the Emerging Growth Conference (GlobeNewswire)
May-03-24 06:00AM	Immuron Director Resignation (GlobeNewswire)
Apr-15-24 06:00AM	Immuron to host Live Virtual Event (GlobeNewswire)
Apr-10-24 06:00AM	Immuron Travelan sales continued strong growth (GlobeNewswire) +8.53%
Mar-07-24 06:00AM	Immuron Announces Positive Results Support Travelan progress to Phase 3 Clinical Trials in the US (GlobeNewswire) +175.74%
Feb-21-24 06:00AM	Immuron Presentation Australian Biologics Festival 2024 (GlobeNewswire)
Feb-13-24 06:00AM	Immuron achieves record Travelan sales (GlobeNewswire)
Feb-08-24 06:00AM	Immuron CEO, Steven Lydeamore Investor Webinar Presentation (GlobeNewswire)
Jan-16-24 06:00AM	Immuron achieves record half yearly Travelan sales (GlobeNewswire)
Dec-22-23 06:00AM	Immuron Clinical Trials Update (GlobeNewswire)
Dec-04-23 06:00AM	Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study (GlobeNewswire)
Nov-28-23 06:33AM	Immuron CEO, Steven Lydeamore Investor Webinar Presentation (GlobeNewswire) +5.70%
Nov-13-23 06:00PM	Immuron CEO Steven Lydeamore Investor Webinar Presentation (GlobeNewswire) +6.25% +11.18%
Oct-30-23 07:21AM	Immuron CEO Steven Lydeamore presented at AusBioInvest (GlobeNewswire)
Oct-18-23 06:00AM	Immuron Announces Travelan Clinical Study Cohort 2 commences (GlobeNewswire)
Oct-11-23 06:00AM	Immuron achieves record quarterly Travelan sales (GlobeNewswire)
Sep-18-23 07:30AM	Immuron Limited Announces Participation in the LD Micro Main Event XVI (Newsfile)
Sep-14-23 01:30PM	Immuron hails record monthly sales of Travelan (News Direct)
Sep-13-23 06:00AM	Immuron achieves record monthly Travelan® sales (GlobeNewswire)
Sep-11-23 06:00AM	Immuron CEO, Steven Lydeamore to present at H.C. Wainwright (GlobeNewswire)
Aug-23-23 08:30AM	Planet MicroCap Review Magazine for Summer 2023 Now Online (ACCESSWIRE)
Aug-14-23 06:00AM	Immuron to present at the Military Health System Research Symposium (GlobeNewswire)
Jul-26-23 02:45PM	Immuron welcomes launch of Travelan on Amazon US (News Direct)
Jul-25-23 06:00AM	Immuron Announces First Patients Enrolled in Travelan® Clinical Study (GlobeNewswire)
Jul-24-23 06:00AM	Immuron CEO, Steven Lydeamore to present at Bioshares (GlobeNewswire)
Jul-19-23 08:30AM	Immuron Ltd. Describes How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales Announcement in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jul-11-23 06:00AM	Immuron Business Update - Ateria Health launches Juvia in Australia (GlobeNewswire)
Jul-05-23 06:00AM	Immuron FY23 Sales increase 136% on FY22 Sales (GlobeNewswire) +7.44%
Jun-30-23 06:00AM	Immuron Chairman Transition (GlobeNewswire) +6.31%
Jun-22-23 06:00AM	Immuron Business Update: Letter to Shareholders (GlobeNewswire)
May-30-23 06:00AM	Immuron Initiates Recruitment of Travelan® Clinical Study (GlobeNewswire)
May-16-23 07:30AM	Immuron Limited Announces Participation in the LD Micro Invitational XIII (Newsfile) +5.80%
May-08-23 01:11PM	FDA Lifts Clinical Hold From Immuron's New Campylobacter ETEC Therapeutic Study (Benzinga) +43.32%
06:00AM	Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation (GlobeNewswire)
May-02-23 06:00AM	Immuron CEO, Steven Lydeamore to present at Coffee Microcaps (GlobeNewswire) -9.76%
Apr-19-23 06:00AM	Immuron Q3 FY23 Business Update Presentation (GlobeNewswire) -10.65%
Apr-11-23 06:00AM	Q3 FY23 Business Update Webinar Notification (GlobeNewswire)
Apr-06-23 06:00AM	Immuron Q3 Sales reach 150% of 1H Sales (GlobeNewswire)
Feb-15-23 06:00AM	Immuron CEO, Steven Lydeamore to host an investor webinar (GlobeNewswire)
Jan-25-23 06:00AM	Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic (GlobeNewswire)
Jan-18-23 05:00AM	US Department of Defense Uniformed Services University Clinical Evaluation of Travelan Achieves 150 Recruitment Milestone (GlobeNewswire)
Jan-17-23 07:10AM	Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease (GlobeNewswire)

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group's R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

M.B.A.Mr. Steven George Lydeamore CPA

Chief Operating OfficerDr. Jerry Kanellos Ph.D.

Chief Commercial OfficerMr. Flavio Palumbo

Chief Financial OfficerMr. Aaron Laurita

Head of MarketingMr. David Lyon

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRN

Immuron Limited ADR

Upgrade your Finviz experience